You Might Also Like: Morning Brew Daily

**Neil Freiman** (0:01)
Good Morning Brew Daily Show, I'm Neil Freiman.

**Toby Howell** (0:04)
And I'm Toby Howell.

**Neil Freiman** (0:05)
Today, it could get a lot easier to add peptides to your medicine cabinet.

**Toby Howell** (0:08)
Then, the open verse closed debate is splitting the AI world in two.
It's Monday, July 27th. Let's ride.

**Neil Freiman** (0:24)
Good morning and welcome back to the week. You know, Toby, I thought I was done with school forever, but a new program from Arizona State is getting a bunch of attention. The school, famous for its party culture, is launching the first ever bachelor's degree in content creation, which according to the website, quote, prepares you to become an influencer and strategic storyteller who thrives in the rapidly evolving creator economy. Administrators say, joke, all you want about a degree in influencing. This is a useful way to build skills in this rapidly evolving media environment. And if you want to pad your resume even more, they're even offering a minor in Rizzler appreciation.

**Toby Howell** (1:00)
I gotta see what this class load looks like. Man, I'd love to go to this party, but I got an 8 a.m. seminar on ring light setup. Dude, I'm way behind on my Mr. Beast face thumbnail practice. Obviously, it's easy to joke about, but learning multimedia production and how to communicate effectively in today's day and age is absolutely a marketable corporate skill, so you can roll your eyes, but Becky and Chad, who took TikTok 101, will likely either be famous or gainfully employed by a Big Five accounting firm before you know it. And now a word from our sponsor, Anthropic, the team behind Claude. Neil, what do you think people actually want from AI?

**Neil Freiman** (1:40)
More hours in the day?

**Toby Howell** (1:41)
Close. When Anthropic, the public benefit corporation behind Claude, ran a massive AI interview study, people's hopes were surprisingly human. More time with family, learning the thing they never got to learn, finally starting that business.

**Neil Freiman** (1:55)
And the fears?

**Toby Howell** (1:56)
More of the same, hopeful and worried all at once.

**Neil Freiman** (1:59)
Which is why Anthropic takes both seriously. They're asking hard questions and doing the work, so the future people hope for is the one that shows up.

**Toby Howell** (2:06)
So head to claude.ai/mbd to share your own hopes for AI's future and see what people around the world said. That's C-L-A-U-D-E dot AI slash MBD.

**Neil Freiman** (2:19)
The peptide floodgates could soon be opened. Late last week, an FDA advisory committee voted in favor of loosening restrictions on six peptides, despite the FDA's own scientists recommending against it. If the agency ultimately approves the recommendation, as expected, it could lead to a windfall for telehealth companies eager to grab a slice of this booming corner of the wellness world. Peptides are a broad category of short chain amino acids that are produced in the human body and can also be made synthetically. Some approved peptides like insulin or GLP-1 weight loss drugs have proven miraculous for public health. But recently a wave of unapproved peptides with names like BPC-157 are being marketed as remedies for everything from wrinkles to a pulled hamstring. These peptides are being sold through a regulatory loophole on the gray market, mostly by Chinese manufacturers pitching them as quote, for research use only. Proponents of improving access to peptides who include wellness influencers like Joe Rogan and Health Secretary RFK. Jr. say, Look, people are using peptides anyway. Demand is booming. We might as well bring this above board to create safer, more transparent products. Opponents like the FDA scientists counter that there is basically no paper trail, no clinical evidence of these peptides actually improving health outcomes. Plus, they point to what seems to be a glaring conflict of interest in the makeup of this advisory panel. RFK. Jr. appointed eight new members. Of them, six run clinics that offer peptides. Debbie, it's about to be an amino acid gold rush.

**Toby Howell** (3:44)
You know what the historic parallel that comes to mind here? It's the vitamin industry. If you go back to the early 1990s, it was in a very similar position that peptides are now, which were they were trying to organize this big lobbying campaign to keep Congress from putting FDA oversight on them, essentially. Congress did respond with a law that exempted supplements from the same requirements pharmaceutical companies face. Fast forward to today. Supplement industry is a $70 billion market with lots of beneficial projects, but also lots of gray area. So maybe that's the future that we are steaming towards as you kind of have this expanded support for peptides. Again, not all peptides are inherently bad, but if they are less regulated, then you start to get some of the gray areas that some critics are saying, that's what we should watch out for.